Liprolog Mix50

Insulin lispro, the active ingredient in Liprolog Mix50, is a rapid‑acting insulin analog presented as a subcutaneous injectable formulation for subcutaneous use. It is used to control blood glucose in adults and children with type 1 or type 2 diabetes mellitus. The product is manufactured for the European Union market and meets EU regulatory standards.

GNH USA supplies Liprolog Mix50 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liprolog Mix50, a rapid‑acting insulin analog, is used to manage hyperglycaemia in diabetes mellitus. - Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces risk of hyperglycaemic episodes. - Type 2 diabetes mellitus: assists in achieving glycaemic targets when combined with oral agents or basal insulin.

Liprolog Mix50 may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, often presenting with sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in subcutaneous fat tissue. - Weight gain: modest increase in body weight over time.

Serious or Rare Side Effects: - Severe hypoglycaemia: prolonged loss of consciousness or seizures. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Lipohypertrophy with repeated injections causing large fatty deposits.

When prescribing Liprolog Mix50, clinicians should consider several safety measures to minimise risks. - Dose adjustment: tailor the insulin dose to individual carbohydrate intake and blood glucose monitoring. - Hypoglycaemia risk: educate patients on recognising and treating low blood glucose promptly. - Renal impairment: monitor kidney function and adjust dose if necessary. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro can interact with other medicines, altering its glucose‑lowering effect or increasing adverse events.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms, requiring closer monitoring. - MAO‑B inhibitors (e.g., selegiline): can potentiate insulin’s hypoglycaemic effect.

Moderate Interactions (Monitor Closely): - Oral hypoglycaemic agents (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect may increase hypoglycaemia risk. - Corticosteroids: may raise blood glucose, necessitating dose adjustments. - Thiazide diuretics: can impair glucose tolerance, requiring closer glucose monitoring.